A Phase 4 interventional study of EXPAREL and Bupivacaine and Standard of Care in Postoperative Pain Management, sponsored by Pacira Pharmaceuticals, Inc. Terminated at 12 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-09.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative — 14 open to participants now, 15 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain, Postoperative.
Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, this one is the 58th largest by enrollment, is one of 15 that started in 2019, is one of 52 in phase 4, and was the 56th registered.
5,662 studies on the registry are indexed under Pain, Postoperative; 1,238 are open to participants now.
Browse Pain, Postoperative studies →14 of the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Tianjin First Central Hospital · Sites in China
Ages 18–80
Texas Scottish Rite Hospital for Children · Sites in United States
Ages 13–21
Boston Children's Hospital · Sites in United States
Ages 10–17
Texas Tech University Health Sciences Center · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 328 (48%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 16 · Phase 4 52
First in 2012; this study’s year is marked. 15 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is below the median of 75 across 4,841 interventional studies indexed under Pain, Postoperative.
Median enrollment 80 across the 93 interventional studies. Of the 61 that completed or were terminated, 41 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 93 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 17 (63%) have results posted.
25 studies in Pain, Postoperative by Pacira BioSciences, Inc.: 1 open now, 1 under way, none of them phase 3. Of 24 finished, 19 (79%) have results posted.
Among the 25 studies in Pain, Postoperative by Pacira BioSciences, Inc., this one is the 13th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2019, is one of 6 in phase 4, and was the 23rd registered.
Pacira BioSciences, Inc.’s Pain, Postoperative studies by the year they started, since 2004.
8 of the studies testing Liposomal Bupivacaine in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT03737292Milton S. Hershey Medical CenterLiposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | 2026-12 |
| NCT06271265Pacira Pharmaceuticals, IncStudy to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery | 2027-01 |
| NCT07689162Washington University School of MedicineLiposomal Bupivacaine vs Standard Bupivacaine for Post-Rhinoplasty Analgesia | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, from their registry updates:
Among Pacira BioSciences, Inc.’s 25 in Pain, Postoperative:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective: The primary objective of this study is to compare postsurgical opioid consumption through 72 hours postsurgery in patients receiving local infiltration analgesia (LIA) with EXPAREL and bupivacaine HCl (EXPAREL group) with that of patients receiving standard of care (SOC) (control group) in adult subjects undergoing posterior lumbar spine surgeries where both groups are receiving a multimodal pain regimen.
Secondary Objectives: The secondary objectives of this study are to:
This is a Phase 4, multicenter, prospective, active-controlled, real world, study in approximately 225 adult subjects undergoing posterior lumbar spine surgery under general anesthesia.
Subjects will be screened within 30 days prior to surgery; screening on the day of surgery will be allowed but is discouraged. If a subject can only be screened on the day of surgery, the informed consent process must still be started at least 24 hours prior to the conduct of any screening procedures that are not considered SOC at the institution and such procedures may not be performed until written informed consent is provided. All screening procedures that are not SOC must be performed and documented within the 30-day time window (inclusive of the day of surgery for those subjects who can only be screened on the day of surgery) as described here.
During the screening visit, subjects will be assessed for any past or present medical conditions that in the opinion of the investigator would preclude them from study participation. After the ICF is signed, the following information will be recorded and procedures done: medical history, surgical history, medication history, the subject's opioid use history will be recorded to calculate mean daily mg oral morphine equivalent dosing (MED PO) in the last 30 days, demographic and background information, height, weight and body mass index (BMI), a urine pregnancy test for women of childbearing potential, and the subject's current adverse experiences (AEs), if any.
Subjects will be asked questions and/or be asked to fill forms as part of the following assessments: Brief Pain Inventory - short form (BPI-sf), 5-item Opioid Compliance Checklist (OCC), Hospital Anxiety and Depression Scale (HADS), Survey of Pain Attitudes (SOPA), Numeric Rating Scale (NRS) ti assess pain and Opioid Related Symptom Distress Scale (ORSDS).
Based on the planned surgical procedure, subjects will be placed in one of three cohorts:
The initial sample size in each study cohort (i.e., cohort 1, cohort 2 and cohort 3) is estimated at 75 subjects (50 subjects with EXPAREL and 25 subjects with Control group), for a total of 225 subjects in all three cohorts. Within each assigned cohort, subjects will be allocated in a 2:1 ratio to the EXPAREL (50 subjects) and Control group (25 subjects).
The following sequence will be followed for all cohorts: First, the subjects who meet eligibility criteria will be treated according to the institution's SOC. Their data will be collected prospectively. Next, at each investigational site, the administration of EXPAREL and bupivacaine HCl to the first 1 to 3 subjects in each cohort will be observed to ensure that the correct procedure for infiltration as described in the infiltration guide is being followed. If the infiltration was performed correctly, the subject will be included in the study. If the infiltration was performed incorrectly, the subject will continue in the study but will be removed from statistical analysis and will be replaced to ensure at least 50 evaluable EXPAREL patients are enrolled per cohort. If subjects are discontinued for other reasons, they will be replaced such that a total sample size of 75 fully evaluable subjects is obtained in each study cohort, with 50 in the EXPAREL group and 25 in the Control group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Primary surgical indication is related to spinal degenerative disease, including any of the following:
Scheduled to undergo:
Cohort 1 - Open only:
Open or mini-open surgical technique with:
Cohort 2 - Tubular or percutaneous cohort only:
Cohort 3 - Lumbar decompression without fusion outpatient cohort only:
Exclusion Criteria:
Serious spinal pathology determined by Investigator that might meaningfully affect postsurgical outcomes, including any of the following:
Anterior surgical approaches, including any of the following:
Lateral surgical approaches, including any of the following:
High-dose presurgical opioid use:
a) Mean daily intake greater than 100 mg mEq PO in the past 30 days
Known allergy, , or contraindication to any of the following study medications:
In addition, the subject might be excluded from the study prior to study drug infiltration if one of the following criteria during the surgical procedure is met:
In addition, the subject must be considered an early termination if one of the following criteria after the surgical procedure is met:
Intraoperative complications likely to meaningfully affect postsurgical outcomes, including any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
Drug: EXPAREL and Bupivacaine · Drug: Standard of Care
Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
Drug: EXPAREL and Bupivacaine · Drug: Standard of Care
Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
Drug: EXPAREL and Bupivacaine · Drug: Standard of Care
Drug page: Liposomal Bupivacaine
Drug: EXPAREL and Bupivacaine HCl 0.5%
Standard of Care
Post-surgical Opioid Consumption in mg MED PO (0-72 Hours)
Post-surgical opioid consumption in mg MED PO from 0 hours (end of surgery) to 72 hours postsurgery
Time frame: 0-72 hours
Post-surgical Opioid Consumption in mg MED PO at 14 Days After Surgery
Post-surgical opioid consumption in mg MED PO at 14 days after surgery
Time frame: 0-14 days after surgery
Time to First Opioid Rescue Through 72 Hours or Discharge.
Time to first opioid rescue through 72 hours or discharge.
Time frame: 0-72 hours
| Milestone | Cohort 1:Open or Mini-open Surgical Technique | Cohort 1 Control Group | Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort) | Cohort 2 Control Group | Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort) | Cohort 3 Control Group |
|---|---|---|---|---|---|---|
| Started | 0 | 17 | 0 | 3 | 13 | 32 |
| Completed | 0 | 15 | 0 | 1 | 13 | 25 |
| Not completed | 0 | 2 | 0 | 2 | 0 | 7 |
| Withdrew: Problems with ediary | 0 | 1 | 0 | 1 | 0 | 4 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Not treated -study terminated by sponsor | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Surgery cancelled | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 |
Post-surgical opioid consumption in mg MED PO from 0 hours (end of surgery) to 72 hours postsurgery
| MED, mg | Cohort 1:Open or Mini-open Surgical Technique | Cohort 1 Control Group | Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort) | Cohort 2 Control Group | Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort) | Cohort 3 Control Group |
|---|---|---|---|---|---|---|
| Post-surgical Opioid Consumption in mg MED PO (0-72 Hours) | — | 90.7 ± 96.91 | — | 56.8 ± 5.30 | 51.6 ± 60.98 | 83.6 ± 109.84 |
Post-surgical opioid consumption in mg MED PO at 14 days after surgery
| MED, mg | Cohort 1:Open or Mini-open Surgical Technique | Cohort 1 Control Group | Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort) | Cohort 2 Control Group | Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort) | Cohort 3 Control Group |
|---|---|---|---|---|---|---|
| Post-surgical Opioid Consumption in mg MED PO at 14 Days After Surgery | — | 279 ± 330.66 | — | 330.8 ± 42.78 | 158.4 ± 242.71 | 187.7 ± 252.40 |
Time to first opioid rescue through 72 hours or discharge.
| hours | Cohort 1:Open or Mini-open Surgical Technique | Cohort 1 Control Group | Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort) | Cohort 2 Control Group | Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort) | Cohort 3 Control Group |
|---|---|---|---|---|---|---|
| Time to First Opioid Rescue Through 72 Hours or Discharge. | — | 0.82 (0.58 to 8.02) | — | 0.36 (0.03 to 0.68) | 3.07 (0.60 to 25.10) | 0.95 (0.83 to 1.52) |
Collected over AEs were collected from time of signing informed consent to Day 30 phone call.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1:Open or Mini-open Surgical Technique | — | — | — |
| Cohort 1 Control Group | 0/16 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort) | — | — | — |
| Cohort 2 Control Group | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort) | 0/13 (0%) | 1/13 (7.7%) | 8/13 (61.5%) |
| Cohort 3 Control Group | 0/30 (0%) | 1/30 (3.3%) | 19/30 (63.3%) |
| Event | Cohort 1:Open or Mini-open Surgical Technique | Cohort 1 Control Group | Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort) | Cohort 2 Control Group | Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort) | Cohort 3 Control Group |
|---|---|---|---|---|---|---|
| Cauda equina syndromeNervous system disorders | — | — | — | — | 1/13 | 1/30 |
| Lumbar Spinal StenosisMusculoskeletal and connective tissue disorders | — | — | — | — | 0/13 | 1/30 |
| Spinal epidural haematomaNervous system disorders | — | — | — | — | 0/13 | 1/30 |
| Event | Cohort 1:Open or Mini-open Surgical Technique | Cohort 1 Control Group | Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort) | Cohort 2 Control Group | Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort) | Cohort 3 Control Group |
|---|---|---|---|---|---|---|
| SomnolenceNervous system disorders | — | 0/16 | — | 0/2 | 0/13 | 9/30 |
| ConstipationGastrointestinal disorders | — | 2/16 | — | 0/2 | 2/13 | 7/30 |
| Disturbance in attentionNervous system disorders | — | 0/16 | — | 0/2 | 0/13 | 5/30 |
| FatigueGeneral disorders | — | 0/16 | — | 0/2 | 0/13 | 5/30 |
| Stitch abcessInfections and infestations | — | 0/16 | — | 0/2 | 2/13 | 0/30 |
| NauseaGastrointestinal disorders | — | 0/16 | — | 0/2 | 1/13 | 4/30 |
| DizzinessNervous system disorders | — | 0/16 | — | 0/2 | 1/13 | 3/30 |
| DysuriaRenal and urinary disorders | — | 0/16 | — | 0/2 | 0/13 | 3/30 |
| Peripheral swellingGeneral disorders | — | 0/16 | — | 0/2 | 1/13 | 0/30 |
| Postoperative wound complicationInjury, poisoning and procedural complications | — | 0/16 | — | 0/2 | 1/13 | 0/30 |
Trial was terminated, not all arms had participants enrolled.
| Age, Continuous(years) | Cohort 1:Open or Mini-open Surgical Technique | Cohort 1 Control Group | Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort) | Cohort 2 Control Group | Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort) | Cohort 3 Control Group | Total |
|---|---|---|---|---|---|---|---|
| Mean | — | 60.94 (47 to 75) | — | 56 (53 to 60) | 52.38 (22 to 74) | 52.66 (21 to 72) | 55.495 (21 to 75) |
| Sex: Female, Male(Participants) | Cohort 1:Open or Mini-open Surgical Technique | Cohort 1 Control Group | Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort) | Cohort 2 Control Group | Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort) | Cohort 3 Control Group | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 8 | 0 | 0 | 9 | 11 | 28 |
| Male | 0 | 9 | 0 | 3 | 4 | 21 | 37 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1:Open or Mini-open Surgical Technique | Cohort 1 Control Group | Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort) | Cohort 2 Control Group | Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort) | Cohort 3 Control Group | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 16 | 0 | 3 | 12 | 27 | 58 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 | 5 | 7 |
| Race (NIH/OMB)(Participants) | Cohort 1:Open or Mini-open Surgical Technique | Cohort 1 Control Group | Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort) | Cohort 2 Control Group | Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort) | Cohort 3 Control Group | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | — | 0 | — | 0 | 0 | 0 | 0 |
| Asian | — | 0 | — | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | — | 0 | — | 0 | 0 | 0 | 0 |
| Black or African American | — | 1 | — | 0 | 0 | 1 | 2 |
| White | — | 15 | — | 3 | 12 | 29 | 59 |
| More than one race | — | 0 | — | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | — | 1 | — | 0 | 1 | 2 | 4 |
| Region of Enrollment(participants) | Cohort 1:Open or Mini-open Surgical Technique | Cohort 1 Control Group | Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort) | Cohort 2 Control Group | Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort) | Cohort 3 Control Group | Total |
|---|---|---|---|---|---|---|---|
| United States | — | 17 | — | 3 | 13 | 32 | 65 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2019 to primary completion in Aug 2020, 12 months.
Results were first posted in Nov 2021, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal Bupivacaine